Albert Ferrer
Founding Partner @ Invivo Capital Partners
Barcelona, Spain
Albert Ferrer is a seed investor at Invivo Capital Partners in Barcelona focused on Biotechnology and SaaS. Albert Ferrer is the Founding Partner at Invivo Ventures.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Albert Ferrer invests in
Stages Albert Ferrer invests in
Countries Albert Ferrer invests in
Round sizes
Round size
- Seed
- $585k–$4.7M
Investment Focus
Industry
- Biotechnology 5 (42%)
- SaaS 1 (8%)
- Software 1 (8%)
- Health Care 1 (8%)
- Life Science 1 (8%)
Stage
- Seed 6 (50%)
- Angel 1 (8%)
- Series A 1 (8%)
- Series B 1 (8%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Telum Therapeutics
|
Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M / Series A / Jul 01, 2026 | |
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | |
Gyala Therapeutics
|
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytesare obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas. | $3.3M / Venture - Series Unknown / Oct 14, 2024 | |
|
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $46.5M / Series B / May 03, 2023 | |
Premiumguest
|
Premiumguest replaces manual processes with software that allows you to sell tickets under your own brand, establish your own database, manage sales channels or public relations, develop an interactive map for seat or table bookings, and a variety of marketing tools to help you sell more. | $1.1M / Angel / Jun 27, 2022 | |
|
Premiumguest
|
Premiumguest replaces manual processes with software that allows you to sell tickets under your own brand, establish your own database, manage sales channels or public relations, develop an interactive map for seat or table bookings, and a variety of marketing tools to help you sell more. | $584.8K / Seed / Sep 27, 2021 | |
|
Telomere Therapeutics
|
Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis | $1.8M / Seed / Dec 01, 2020 | |
|
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $5M / Seed / Jul 24, 2020 | |
|
Telum Therapeutics
|
Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $4.7M / Seed / Jul 13, 2020 | |
|
Gyala Therapeutics
|
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytesare obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas. | $1.6M / Seed / May 26, 2020 | |
| See all 12 investments → | |||
Co-Investors
About Invivo Capital Partners
Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.
Invivo Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Albert Ferrer
Founding Partner
|
|||
Lluis Pareras
Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Albert Ferrer invest in?
Albert Ferrer invests primarily in Biotechnology, SaaS and Software startups, most often at Seed and Angel stage. Most of the 12 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Albert Ferrer's check size?
Albert Ferrer typically joins rounds of $585k–$4.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Albert Ferrer participates in.
When did Albert Ferrer last invest?
The most recent investment recorded for Albert Ferrer closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
